NZ598441A - Boron-containing small molecules - Google Patents

Boron-containing small molecules

Info

Publication number
NZ598441A
NZ598441A NZ598441A NZ59844106A NZ598441A NZ 598441 A NZ598441 A NZ 598441A NZ 598441 A NZ598441 A NZ 598441A NZ 59844106 A NZ59844106 A NZ 59844106A NZ 598441 A NZ598441 A NZ 598441A
Authority
NZ
New Zealand
Prior art keywords
benzoxaborole
hydroxy
dihydro
cyanophenoxy
phenoxy
Prior art date
Application number
NZ598441A
Other languages
English (en)
Inventor
Stephen J Baker
Tsutomu Akama
Carolyn Bellinger-Kawahara
Vincent S Hernandez
Karin M Hold
James J Leyden
Kirk R Maples
Jacob J Plattner
Virginia Sanders
Yong-Kang Zhang
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of NZ598441A publication Critical patent/NZ598441A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ598441A 2005-02-16 2006-02-16 Boron-containing small molecules NZ598441A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
NZ598441A true NZ598441A (en) 2013-07-26

Family

ID=36917059

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ560448A NZ560448A (en) 2005-02-16 2006-02-16 Boron-containing small molecules
NZ598441A NZ598441A (en) 2005-02-16 2006-02-16 Boron-containing small molecules
NZ578297A NZ578297A (en) 2005-02-16 2006-02-16 Boron-containing small molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ560448A NZ560448A (en) 2005-02-16 2006-02-16 Boron-containing small molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ578297A NZ578297A (en) 2005-02-16 2006-02-16 Boron-containing small molecules

Country Status (25)

Country Link
US (11) US7582621B2 (en:Method)
EP (4) EP1853251B1 (en:Method)
JP (6) JP5038912B2 (en:Method)
KR (4) KR101456815B1 (en:Method)
CN (2) CN101160124A (en:Method)
AU (3) AU2006214247C1 (en:Method)
BR (1) BRPI0608431B8 (en:Method)
CA (1) CA2597982C (en:Method)
CY (3) CY1120695T1 (en:Method)
DK (3) DK2987796T3 (en:Method)
ES (4) ES2872962T3 (en:Method)
FR (1) FR20C1024I2 (en:Method)
HU (4) HUE054365T2 (en:Method)
IL (2) IL207156A (en:Method)
LT (1) LTC2343304I2 (en:Method)
LU (1) LUC00157I2 (en:Method)
MX (1) MX369262B (en:Method)
NL (1) NL301049I2 (en:Method)
NZ (3) NZ560448A (en:Method)
PL (4) PL1853251T3 (en:Method)
PT (4) PT3424932T (en:Method)
RU (3) RU2414906C2 (en:Method)
SI (3) SI3424932T1 (en:Method)
WO (1) WO2006089067A2 (en:Method)
ZA (4) ZA200707408B (en:Method)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
SI3424932T1 (sl) * 2005-02-16 2021-08-31 Anacor Pharmaceuticals, Inc. Boronoftalidi za terapevtsko uporabo
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
CA2635680A1 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP1988779B1 (en) 2006-02-16 2015-06-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
EP2187893A4 (en) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2009126691A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010011354A2 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
CA2744231A1 (en) 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
EP2416660B1 (en) * 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX2012001156A (es) 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022337A1 (en) 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) * 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (en) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antihelminth agents
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
US8680136B2 (en) 2010-08-10 2014-03-25 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL3251678T3 (pl) 2010-09-07 2022-01-10 Anacor Pharmaceuticals, Inc. Pochodne benzoksaborolu do leczenia zakażeń bakteryjnych
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013049424A1 (en) 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
US10130096B2 (en) 2011-10-07 2018-11-20 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101666331B1 (ko) * 2013-01-30 2016-10-13 다우 아그로사이언시즈 엘엘씨 육류, 식물, 또는 식물 부분에 대한 휘발성 항미생물제로서의 벤족사보롤의 용도
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
WO2014121124A1 (en) 2013-02-01 2014-08-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
SI3030519T1 (sl) * 2013-08-09 2022-04-29 Glaxosmithkline Intellectual Property (No.2) Limited Triciklične benzoksaborolne spojine in njihove uporabe
SG11201602596UA (en) 2013-10-03 2016-04-28 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions
KR20160087898A (ko) 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
WO2015121442A1 (en) 2014-02-17 2015-08-20 Syngenta Participations Ag Microbiocidally active benzoxaboroles
US10065029B2 (en) 2014-03-03 2018-09-04 Cook Medical Technologies Llc Mechanical dilator
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2954803A1 (en) * 2014-05-12 2015-11-19 Agrofresh Inc. Volatile applications against pathogens
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TW201625649A (zh) 2014-07-01 2016-07-16 第一三共股份有限公司 作爲抗菌劑的三環化合物
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PL3209319T3 (pl) 2014-10-21 2021-12-20 Hexima Limited Sposób leczenia zakażeń grzybiczych
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
CN107567456A (zh) 2015-04-09 2018-01-09 安纳考尔医药公司 作为抗原虫剂的含硼小分子
CN107872956B (zh) 2015-04-09 2020-07-10 宾夕法尼亚州研究基金会 含有苯并氧杂硼戊环的协同性抗真菌组合物
US11174267B2 (en) 2015-06-12 2021-11-16 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US10160867B2 (en) * 2015-08-06 2018-12-25 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
PT3383363T (pt) 2015-11-30 2021-03-03 Anacor Pharmaceuticals Inc Formulações farmacêuticas tópicas para o tratamento de afeções relacionadas com inflamações
CN109152932B (zh) * 2016-03-02 2021-09-28 比尔及梅琳达盖茨基金会 含硼小分子
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
CN113321672A (zh) * 2016-03-02 2021-08-31 比尔及梅琳达盖茨基金会 含硼小分子
TW201733442A (zh) 2016-03-07 2017-10-01 農業保鮮股份有限公司 殺有害生物劑之汽化給予
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
JP2019520321A (ja) * 2016-05-09 2019-07-18 アナコール ファーマシューティカルズ，インコーポレイテッド フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
KR102403296B1 (ko) 2016-06-30 2022-05-27 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 치료적 용도
US20170305936A1 (en) 2016-07-12 2017-10-26 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (en) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Crisaborole production process
AU2018230580A1 (en) * 2017-03-09 2019-09-19 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
WO2018207216A1 (en) 2017-05-12 2018-11-15 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (crisaborole)
US10865217B2 (en) 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
PL3704100T3 (pl) 2017-11-02 2024-04-22 Halcyon Labs Private Limited Nowy sposób wytwarzania tawaborolu i jego związków pośrednich
US11834466B2 (en) * 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) * 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
CA3087139A1 (en) 2018-01-09 2019-07-18 Halcyon Labs Private Limited Process for the preparation of crisaborole and its intermediates
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
CN112384201A (zh) * 2018-07-31 2021-02-19 Mc2疗法有限公司 局部组合物
JP2021534247A (ja) 2018-08-18 2021-12-09 ボラゲン，インコーポレーテッド 置換ベンゾキサボロールの固体形態およびその組成物
CN113166177B (zh) 2018-10-05 2024-09-03 辉瑞公司 含硼的pde4抑制剂
WO2020187803A1 (en) 2019-03-20 2020-09-24 Rita Dobmeyer Pharmaceutical composition
WO2021015841A1 (en) * 2019-07-25 2021-01-28 Massachusetts Institute Of Technology Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
US20230340530A1 (en) 2020-08-31 2023-10-26 Pfizer Inc. Methods of Protecting RNA
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
WO2023246841A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
US6632955B1 (en) 1996-12-02 2003-10-14 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP2223920A3 (en) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
AU4486097A (en) 1996-09-19 1998-04-14 Board Of Trustees Of The Leland Stanford Junior University Dna adenine methyltransferases and uses thereof
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
IL142584A0 (en) 1998-11-06 2002-03-10 Basf Ag Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000044387A1 (fr) 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
EP1181291A2 (en) 1999-05-25 2002-02-27 The Penn State Research Foundation Dna methyltransferase inhibitors
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
AU775940B2 (en) 1999-08-25 2004-08-19 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2001049303A1 (en) 2000-01-06 2001-07-12 Marantech Holding, Llc Multivalent electron active compositions and methods of making and using same
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2002006316A2 (en) 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP2004524281A (ja) 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
JP4342178B2 (ja) 2001-04-06 2009-10-14 バイオクリスト・ファマシューティカルズ インク． セリンプロテアーゼ阻害剤としてのビアリール化合物
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
JPWO2003033002A1 (ja) 2001-10-11 2005-02-03 御子柴　克彦 細胞内カルシウム濃度上昇抑制剤
EP1463739A2 (en) 2002-01-10 2004-10-06 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
US20040077601A1 (en) 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
DE60313357T2 (de) 2002-12-02 2008-01-03 Solvias Ag Verfahren zur katalytischen hydrierung von kohlenstoff-heteroatom-doppelbindungen
BR0317564A (pt) 2002-12-18 2005-11-22 Anacor Pharmaceuticals Inc Compostos, composições e métodos para tratar doenças causadas por bactérias ou fungos
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
BRPI0408256A (pt) 2003-03-14 2006-03-01 Astrazeneca Ab composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
WO2005000200A2 (en) 2003-05-09 2005-01-06 Sugen, Inc. Novel kinases
CA2529792A1 (en) 2003-06-16 2005-02-17 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
CA2530886C (en) 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
US7888349B2 (en) 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
PT1755661E (pt) 2004-05-12 2014-06-03 Brigham & Womens Hospital A utilização de gelsolina para o tratamento de infeções
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
WO2006062731A1 (en) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
SI3424932T1 (sl) * 2005-02-16 2021-08-31 Anacor Pharmaceuticals, Inc. Boronoftalidi za terapevtsko uporabo
US7919422B2 (en) 2005-03-08 2011-04-05 Agency For Science, Technology And Research Chiral bisoxazoline catalysts
US20060251689A1 (en) 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
CA2635680A1 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP1988779B1 (en) 2006-02-16 2015-06-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
RU2008152367A (ru) 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos

Also Published As

Publication number Publication date
HUE040060T2 (hu) 2019-02-28
EP2343304B1 (en) 2015-06-10
EP2987796A1 (en) 2016-02-24
ZA200707408B (en) 2009-11-25
CY2020027I1 (el) 2021-01-27
CY1120695T1 (el) 2019-12-11
US20060234981A1 (en) 2006-10-19
JP2010248265A (ja) 2010-11-04
DK3424932T3 (da) 2021-05-25
FR20C1024I2 (fr) 2021-07-09
RU2016145916A3 (en:Method) 2020-07-21
KR101456815B1 (ko) 2014-10-31
NZ578297A (en) 2010-11-26
HK1109735A1 (en) 2008-06-20
CN101914109B (zh) 2014-07-23
HUE026021T2 (en) 2016-05-30
KR20130100019A (ko) 2013-09-06
CA2597982C (en) 2014-07-08
US20110319361A1 (en) 2011-12-29
ES2540966T3 (es) 2015-07-15
LTPA2020524I1 (lt) 2020-09-10
RU2016145916A (ru) 2018-05-23
IL185080A0 (en) 2008-08-07
KR101426220B1 (ko) 2014-08-05
US20150065459A1 (en) 2015-03-05
EP1853251A2 (en) 2007-11-14
AU2010203096C1 (en) 2012-09-20
RU2010133524A (ru) 2012-02-20
NL301049I1 (nl) 2020-07-01
PL2987796T3 (pl) 2018-12-31
DK2343304T3 (en) 2015-06-29
KR20100105869A (ko) 2010-09-30
ES2686981T3 (es) 2018-10-23
CN101160124A (zh) 2008-04-09
AU2011200994A1 (en) 2011-03-31
EP1853251A4 (en) 2010-01-13
MX369262B (es) 2019-11-04
AU2010203096B2 (en) 2010-12-02
RU2007134429A (ru) 2009-03-27
PT1853251E (pt) 2013-07-19
SI3424932T1 (sl) 2021-08-31
US8440642B2 (en) 2013-05-14
ES2414095T3 (es) 2013-07-18
US20100190748A1 (en) 2010-07-29
RU2414906C2 (ru) 2011-03-27
US7582621B2 (en) 2009-09-01
BRPI0608431A2 (pt) 2009-12-29
JP6046876B2 (ja) 2016-12-21
AU2006214247C1 (en) 2012-11-08
LTC2343304I2 (lt) 2022-11-10
JP2008535781A (ja) 2008-09-04
JP2013018778A (ja) 2013-01-31
PT2987796T (pt) 2018-10-18
US8889656B2 (en) 2014-11-18
US20190048026A1 (en) 2019-02-14
ZA201005380B (en) 2016-08-31
JP2016020374A (ja) 2016-02-04
PT3424932T (pt) 2021-05-19
ES2872962T3 (es) 2021-11-03
CA2597982A1 (en) 2006-08-24
US20140142064A1 (en) 2014-05-22
CY2020027I2 (el) 2021-01-27
EP3424932A1 (en) 2019-01-09
HK1160139A1 (en) 2012-08-10
IL185080A (en) 2012-07-31
EP2343304A1 (en) 2011-07-13
ZA200905950B (en) 2010-11-24
US20190330245A1 (en) 2019-10-31
KR20070112390A (ko) 2007-11-23
BRPI0608431B8 (pt) 2021-05-25
WO2006089067A2 (en) 2006-08-24
NZ560448A (en) 2009-08-28
EP2987796B1 (en) 2018-08-08
JP5038912B2 (ja) 2012-10-03
EP1853251B1 (en) 2013-04-24
AU2006214247B2 (en) 2010-08-05
US20210070780A1 (en) 2021-03-11
JP2014132031A (ja) 2014-07-17
PT2343304E (pt) 2015-08-26
PL3424932T3 (pl) 2021-09-20
AU2006214247A1 (en) 2006-08-24
BRPI0608431B1 (pt) 2020-09-15
KR101337068B1 (ko) 2013-12-06
US20170066788A1 (en) 2017-03-09
AU2010203096A1 (en) 2010-08-12
JP2017105826A (ja) 2017-06-15
NL301049I2 (nl) 2020-09-10
WO2006089067A3 (en) 2007-07-19
KR101337045B1 (ko) 2013-12-05
HUS2000019I1 (hu) 2020-07-28
US20130244980A1 (en) 2013-09-19
IL207156A (en) 2014-04-30
PL1853251T3 (pl) 2013-09-30
SI2343304T1 (sl) 2015-08-31
HUE054365T2 (hu) 2021-09-28
SI2987796T1 (sl) 2018-11-30
US8039451B2 (en) 2011-10-18
EP3424932B1 (en) 2021-04-07
ZA201506944B (en) 2018-08-29
PL2343304T3 (pl) 2015-09-30
CY1124503T1 (el) 2022-07-22
LUC00157I2 (en:Method) 2021-07-06
CN101914109A (zh) 2010-12-15
HK1221956A1 (en) 2017-06-16
LUC00157I1 (en:Method) 2020-06-08
US20160108063A1 (en) 2016-04-21
RU2606947C2 (ru) 2017-01-10
DK2987796T3 (en) 2018-09-17
FR20C1024I1 (en:Method) 2020-07-31
KR20130095330A (ko) 2013-08-27

Similar Documents

Publication Publication Date Title
NZ598441A (en) Boron-containing small molecules
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
DE60222804D1 (de) 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
SE0401342D0 (sv) Therapeutic compounds
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2592345A1 (en) Piperidine and azetidine derivatives as glyt1 inhibitors
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
RU2009127776A (ru) Профилактическое или терапевтическое средство от алопеции
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SG146631A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
TW200510313A (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NO20013480D0 (no) Legemiddel for törr hud

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 16 FEB 2016 BY CPA GLOBAL

Effective date: 20131122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2017 BY DENNEMEYER + CO

Effective date: 20160122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2018 BY DENNEMEYER + CO.

Effective date: 20170120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2019 BY THOMSON REUTERS

Effective date: 20180112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2020 BY THOMSON REUTERS

Effective date: 20190119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2021 BY THOMSON REUTERS

Effective date: 20200116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2022 BY THOMSON REUTERS

Effective date: 20210112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2023 BY THOMSON REUTERS

Effective date: 20211231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2024 BY THOMSON REUTERS

Effective date: 20230103

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2025 BY THOMSON REUTERS

Effective date: 20240102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2026 BY THOMSON REUTERS

Effective date: 20250103